05/11/22 8:00 AMNasdaq : CRBP clinical trialCorbus Presents Latest Preclinical Data for CRB-601 at the New York Academy of Sciences Frontiers in Cancer Immunotherapy ConferenceCRB-601 is a highly potent and selective anti -αvβ8 integrin monoclonal antibody designed to block the activation of TGF b in the local tumor microenvironment Additional non-clinical data demonstrates combination benefit across a diverse range of syngeneic models with differential sensitivity toRHEA-AIneutral
05/10/22 8:00 AMNasdaq : CRBP earningsCorbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate UpdatePromising pre-clinical data generated for CRB-601 across several tumor models as monotherapy and in combination with anti-PD1 therapy IND submission for CRB-601 is on-track for the first half of 2023 Expanding immuno-oncology pipeline through strategic transactions remains key priority Cash andRHEA-AIneutral
04/08/22 1:05 PMNasdaq : CRBP clinical trialCorbus Presents First Preclinical Data for CRB-601 at the American Association for Cancer Research (AACR) Annual MeetingCorbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, announced today the first preclinical data for CRB-601 are being presented in a poster at the American Association for Cancer Research (AACR)RHEA-AIneutral
03/11/22 8:05 AMNasdaq : CRBP conferencesCorbus Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare ConferenceCorbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today announcing that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat at the Oppenheimer 32 nd AnnualRHEA-AIneutral
03/08/22 8:05 AMNasdaq : CRBP earningsCorbus Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate UpdatesCorbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today provided corporate updates and reported financial results for the fourth quarter and year-end of 2021.Key Corporate and ProgramRHEA-AIneutral
12/07/21 8:05 AMNasdaq : CRBP managementCorbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific OfficerCorbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company") today announced the appointment of Rachael Brake, Ph.D., as Chief Scientific Officer, furthering the Company's mission of connecting innovation to purpose. Dr. Brake willRHEA-AIneutral
11/12/21 8:05 AMNasdaq : CRBP earningsCorbus Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate UpdatesCorbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today provided corporate updates and reported financial results for the third quarter of 2021.Key Programs' Updates:Anti-integrin monoclonalRHEA-AIneutral
11/11/21 8:05 AMNasdaq : CRBP conferencesCorbus Pharmaceuticals to Present at the Jefferies London Healthcare ConferenceCorbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat at the Jefferies London HealthcareRHEA-AIneutral
08/12/21 8:05 AMNasdaq : CRBP earningsCorbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate UpdatesCompany focused on gaining regulatory clarity for late-stage lenabasum program and advancing programs targeting the endocannabinoid system and integrin s into the clinic Augmenting the pipeline through business development continues to be a priority Cash and investments on hand of $ 1 14 M providesRHEA-AIneutral
06/24/21 8:05 AMNasdaq : CRBP clinical trialCorbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of DermatomyositisStudy did not meet primary endpoint of Total Improvement Score (TIS) at Week 28 Additional findings included nominally significant improvements in TIS (p = 0.0302) and CDASI (p = 0.0166) depending on the dermatomyositis subtype Lenabasum treatment was safe and well-tolerated in this study Norwood,RHEA-AIneutral